These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3221259)

  • 1. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
    Chamberlain MC; Prados MD; Silver P; Levin VA
    J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
    Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
    J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.
    Castleberry RP; Ragab AH; Steuber CP; Kamen B; Toledano S; Starling K; Norris D; Burger P; Krischer JP
    Invest New Drugs; 1990 Nov; 8(4):401-6. PubMed ID: 2084075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
    Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
    J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
    J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
    Tapazoglou E; Kish J; Ensley J; Al-Sarraf M
    Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
    Creagan ET; Schutt AJ; Ahmann DL; Green SJ
    Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.
    Haid M; Khandekar JD; Christ M; Johnson CM; Miller SJ; Locker GY; Merrill JM; Reisel H; Hatfield A; Lanzotti V
    Cancer; 1985 Sep; 56(6):1311-5. PubMed ID: 4027870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical evaluation of AZQ in renal cell carcinoma.
    Decker DA; Kish J; Al-Sarraf M; Goldfarb S
    Am J Clin Oncol; 1986 Apr; 9(2):126-8. PubMed ID: 3717078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.
    Taylor SA; McCracken JD; Eyre HJ; O'Bryan RM; Neilan BA
    J Neurooncol; 1985; 3(2):131-5. PubMed ID: 2993536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6 -dioxodiethylester) in recurring supratentorial malignant brain gliomas--a Phase II study. EORTC Brain Tumour Cooperative Group.
    Eur J Cancer Clin Oncol; 1985 Jan; 21(1):143-6. PubMed ID: 4038653
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of metastatic breast cancer with AZQ: a phase II trial.
    Martino S; Ratanatharathorn V; Samal BA; Singhakowinta A; Haas C
    Cancer Invest; 1988; 6(3):289-91. PubMed ID: 3167612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
    Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
    Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.
    Høst H; Joss R; Pinedo H; Bruntsch U; Cavalli F; Renard G; van Glabbeke M; Rozencweig M
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):295-8. PubMed ID: 6681775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical evaluation of AZQ in adenocarcinoma of the lung.
    Decker DA; Samson MK; Haas CD; Baker LH
    Am J Clin Oncol; 1984 Aug; 7(4):353-5. PubMed ID: 6741865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II diaziquone chemotherapy in brain tumors.
    Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
    Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
    Sigman LM; Van Echo DA; Whitacre MY; Aisner J; Budman DA; Shulman P
    Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
    Griffin JP; Newman RA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.